Lord Prior, Department of Health minister in charge of relations with pharma and Brexit, discusses exiting the EU, the promised UK Life Sciences strategy and the future of pharma pric
The UK government is to launch a new industrial strategy aimed at helping the country thrive post-Brexit, and life sciences will be ‘centre stage’ when it is unveiled in the spring.
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.